PIK3CA and acute lymphoblastic leukemia: We explored the therapeutic potential of the PI3K pan-inhibitor ZSTK474, the p110α inhibitor BYL719 and dual γ/δ inhibitor IPI145 in a set of Ph+ B-ALL cells.